Qiagen NV | QIA - Operating Profit


Qiagen NV reported $121.88M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.01M 175K Mar/2026
argenx SE USD 394M 22.86M Mar/2026
Avita Medical AUD -10.41M 742K Dec/2025
Dianthus Therapeutics USD -69.54M 29.25M Dec/2025
Ionis Pharmaceuticals USD -118M 97M Mar/2026
IQVIA Holdings USD 565M 2.11B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Organon & Co USD 217M 171M Dec/2025
Qiagen NV USD 121.88M 15.41M Dec/2025
Revvity USD 82.77M 63.06M Mar/2026
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Viatris USD -20.2M 137.3M Mar/2026
Xeris Pharmaceuticals USD 16.77M 10.04M Dec/2025